EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS
Ouf, A., Marzouk, A., Shykhoon, M., El-Zahabi, M. (2023). EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS. EKB Journal Management System, 68(2), 82-110. doi: 10.21608/ajps.2023.332169
Abdelsalam Mohamed Ouf; Adel A Marzouk; Montaser A Shykhoon; Mohamed Ayman ALy El-Zahabi. "EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS". EKB Journal Management System, 68, 2, 2023, 82-110. doi: 10.21608/ajps.2023.332169
Ouf, A., Marzouk, A., Shykhoon, M., El-Zahabi, M. (2023). 'EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS', EKB Journal Management System, 68(2), pp. 82-110. doi: 10.21608/ajps.2023.332169
Ouf, A., Marzouk, A., Shykhoon, M., El-Zahabi, M. EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS. EKB Journal Management System, 2023; 68(2): 82-110. doi: 10.21608/ajps.2023.332169

EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS

Al-Azhar Journal of Pharmaceutical Sciences
Volume 68, Issue 2, September 2023, Page 82-110  XML PDF (1.21 MB)
Document Type: Original Article
DOI: 10.21608/ajps.2023.332169
View on SCiNiTO View on SCiNiTO
Authors
Abdelsalam Mohamed Ouf email 1; Adel A Marzouk1; Montaser A Shykhoon1; Mohamed Ayman ALy El-Zahabiorcid 2
1Department of Pharmaceutical Medicinal Chemistry& Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Assiut 71524, Egypt.
2Al Mockhaim Al Daem street, Nasr 6thdistrict, Cairo Egypt
Abstract
Due to its powerful anticancer characteristics, the heterocyclic quinazoline has attracted a lot of interest in cancer research. Several cancer types, including lung, breast, colon, ovarian, and prostate cancers, have shown promise in response to quinazoline compounds' potential inhibitory properties. Protein tyrosine kinases (PTKs) are one of the main mechanisms through which quinazoline exerts its anticancer effects. Quinazoline drugs can interfere with the signaling pathways that support tumor growth and survival by specifically targeting PTKs. Quinazoline derivatives also exhibit antiangiogenic properties by blocking the vascular endothelial growth factor (VEGF) pathway, which prevents the creation of new blood vessels needed to feed the tumor. Additionally, chemicals derived from quinazolines have the ability to cause cancer cells to undergo apoptosis, or the halt of the cell cycle. Furthermore, quinazolines can accelerate the death of cancer cells while sparing normal, healthy cells through altering the regulation of the cell cycle and pro-apoptotic signaling pathways. Due to their favorable pharmacokinetic profile and low toxicity, they are also promising candidates for further investigation as anticancer agents. More research is required to enhance their efficacy, selectivity, and safety characteristics. Overall, quinazoline and its derivatives have been considered as attractive candidates for further development of novel therapeutic strategies in the field of cancer therapy.
Keywords
Quinazoline; Tyrosine kinases; Serine/threonine kinases; EGFR; VEGFR; Aurora
Supplementary Files
Statistics
Article View: 151
PDF Download: 106